ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / SLDB / financials
FDMT (44) SLBT (45) CADL (33) ATTO (44) ⌘ Pro Terminal →

Solid Biosciences Inc. (SLDB) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$6.20 -2.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.16

Solid Biosciences Inc. (SLDB) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $664.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SLDB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SLDB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Solid Biosciences Inc. (NASDAQ: SLDB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $6.20 (-2.97% 1D, market cap $664.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLDB ranks #904 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SLDB compare to FDMT and SLBT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLDB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FDMT (4D Molecular Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -28.3%, cap $657.4M) and SLBT (SL Science Holding Limited) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $672.9M). Among the 5-stock peer group, SLDB leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SLDB?
▼

Per SLDB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001707502), Solid Biosciences Inc. generated $501.8M in revenue (+38.1% YoY), $0 in net income, and -$157.4M in free cash flow against $232.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.16 (-0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510026
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (4)Whales (4)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.4% Base Target
$12 Bull$5 Base$4 Bear
📬 FREE SLDB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLDB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY SLDB SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (38% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (19% of score)

FRED Regime × Technicals: 31% of 52W Range • RSI-14 at 43 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
18
Grade E$5.82+10% Next Q
Q2 (-2Q)
21
Grade E$6.40-3.3% Next Q
Q3 (-1Q)
23
Grade E$6.19+0.2% Next Q
Current
26
Grade E$6.20-10.5% Hist 90D α
Trajectory: E (18) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLDB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLDB currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.70) and Max Pain ($6.51) forces dealer call-delta covering toward $12.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLDB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SLDB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SLDB Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$501.8MGross Profit $260.9M (52%)Cost of Sales $240.9MOp Profit $0 (0%)OpEx (R&D/SG&A) $260.9MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY24
Rev $363.2M
FY25
Rev $501.8M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$501.8M52%-35.7%$0-$157.4M-45%
FY 2024$363.2M52%-35.7%$0-$100.7M-45%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLDB)

  • ✓Walkthrough of SLDB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SLDB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.25%▼ DESCENDING CHANNEL
2026-11-03O $6.39H $6.39L $6.20C $6.20VOL 873.1K
RES: $9.58SUP: $4.87SMA50: $7.70SMA200: $7.67
$11.87$10.12$8.36$6.60$4.84RES $9.58SUP $4.87$6.202026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLDB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLDB Butterfly Map → + Track SLDB →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SLDB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLDB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SLDB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLDB)

Health Care Rank #904 of 1016 ⚔️ FDMT vs SLDB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLDB vs. FDMT, SLBT, CADL, ATTO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Solid Biosciences Inc. (SLDB) ranks #904 by composite RQD confidence (26/100, grade E) and #402 by equity capitalization ($664.8M). Within this direct 5-issuer industry benchmark cohort, SLDB leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. SLBT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with SLDB at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SLDB ACTIVE
Solid Biosciences Inc.
E 26/100 — — -35.0% -2.97% $664.8M Benchmark Subject
FDMT
4D Molecular Therapeutics Inc.
D 44/100 — — -28.3% -6.89% $657.4M /fdmt-vs-sldb →
SLBT
SL Science Holding Limited
D 45/100 — — — +2.56% $672.9M /slbt-vs-sldb →
CADL
Candel Therapeutics Inc.
E 33/100 — — -35.0% -3.70% $637.4M /cadl-vs-sldb →
ATTO
Attovia Therapeutics Inc.
D 44/100 — — — -0.52% $693.4M /atto-vs-sldb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001707502

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Solid Biosciences Inc. (SLDB) reported GAAP revenue of $501.8M (+38.1% vs. FY2024 revenue of $363.2M ) , GAAP net income of $0, operating cash flow of -$156.3M, and free cash flow of -$157.4M (-56.4% YoY). On the balance sheet, SLDB closed FY2025 with $232.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $501.8M $0 -$156.3M -$157.4M $232.5M —
FY2024 (FY) 2024-12-31 $363.2M $0 -$100.0M -$100.7M $188.7M —

3. SLDB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLDB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Solid Biosciences Inc. (NASDAQ: SLDB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $6.20 (-2.97% 1D, market cap $664.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLDB ranks #904 in composite RQD confidence.

How does SLDB compare to FDMT and SLBT in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLDB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FDMT (4D Molecular Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -28.3%, cap $657.4M) and SLBT (SL Science Holding Limited) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $672.9M). Among the 5-stock peer group, SLDB leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SLDB?

Per SLDB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001707502), Solid Biosciences Inc. generated $501.8M in revenue (+38.1% YoY), $0 in net income, and -$157.4M in free cash flow against $232.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SLDB trading relative to its 50-day, 200-day, and 52-week technical levels?

SLDB last traded at $6.20 (-2.97% on volume of 873,136 shares), positioning the stock -19.48% below its 50-day simple moving average ($7.70) and -19.17% below its 200-day simple moving average ($7.67). Across its 52-week range of $3.79 to $11.45, SLDB sits at the 31.5% percentile with a 14-day RSI of 43.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.42 to $6.98).

Direct Sub-Reports: SLDB RQD Cockpit SLDB 12M Forecast SLDB Earnings & Move SLDB Dividends & DRIP SLDB Insiders & 13F SLDB Whale Options SLDB Profit Sankey SLDB News & Why
ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SLDB — Solid Biosciences Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:33:52Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SLDB scores 27 and carries a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield -22.98%), Whale 13F Flow at 5/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The two weakest pillars, cash generation and insider conviction, indicate that the company is consuming cash without earnings support and that insider activity is not offering a confidence signal. The forensic balance sheet score is the strongest of the five, reflecting a Z-score in the reported range and a moderate Debt/Equity of 0.5, but a Piotroski F-Score of 1/9 signals weak financial health on the rubric's own terms. The rating's message is that downside risk is elevated relative to the reward profile shown in these sources.

Business

Solid Biosciences Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the most prominent items concern European Commission orphan designation for SGT-212 and continued progress in the FALCON trial in Friedreich's Ataxia; this item is flagged RED with a RISK WATCH impact label. Other items, flagged YELLOW with MARKET WIRE labels, include a H.C. Wainwright rating reiteration tied to the EU designation, a Benzinga after-market health care roundup, a Simply Wall St note on cash burn rate, and an ad-hoc-news.de report citing a stock valuation of USD 686.2 million alongside seven presented studies. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What are the company's products, lead programs, and revenue model, given that reported revenue is $0.0M in both periods?
  • What is the company's cash runway at the reported FY 2025 burn rate relative to the $59.9M cash balance?
  • What is the debt balance behind the Debt/Equity ratio of 0.5, given that debt is listed as N/A in the financials?
  • What are the timelines and outcomes for the FALCON trial and the SGT-212 regulatory pathway?
  • What drove the 52-week range of $3.79 to $11.45, and how does the current $6.39 price compare to that history?

SLDB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Solid Biosciences Inc. (SLDB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SLDB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SLDB Bull vs. Bear Conversation Board — What's Your Call at $6.20?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLDB 🐻 67% BEARISH CONVICTION
1. Pick Your Side on SLDB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.62 (-12.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SLDB (E • RQD 27/100) a Buy at $6.39?

Welcome to the SLDB (Solid Biosciences Inc.) Roar Pit. Current RQD Composite is 27/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.86 (-23.9%)
Spot @ $6.39

Pump the brakes on SLDB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SLDB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Solid Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $8.12 (+27.1%)
Spot @ $6.39

SLDB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SLDB, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $6.39 (52-wk range $3.79 - $11.45), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%